MCC950 Sodium: Selective NLRP3 Inflammasome Inhibition in Macrophages and Autoimmune Disease Models

Executive Summary: MCC950 sodium (B7946, APExBIO) is a potent, selective small-molecule inhibitor of the NLRP3 inflammasome with nanomolar efficacy in murine and human macrophages (APExBIO). It blocks both canonical and noncanonical NLRP3 activation pathways while sparing other inflammasomes such as AIM2, NLRC4, and NLRP1 (Yuan et al. 2022). The compound exhibits high solubility (≥124 mg/mL in water) and stability at -20°C with short-term solution usage recommended. MCC950 sodium is validated in cell-based and animal models, demonstrating robust inhibition of IL-1β release and disease attenuation in experimental autoimmune encephalomyelitis. Its specificity and translational relevance position it as a gold standard for research on NLRP3-associated inflammation and autoimmune mechanisms.

Biological Rationale

The NOD-like receptor family protein 3 (NLRP3) inflammasome is a multi-protein complex that detects pathogenic and endogenous danger signals in innate immune cells, particularly macrophages (Yuan et al. 2022). Upon activation, NLRP3 recruits and activates caspase-1, leading to the maturation and secretion of interleukin-1β (IL-1β) and IL-18, and initiating pyroptotic cell death. Dysregulated NLRP3 activity is implicated in a wide spectrum of autoinflammatory, autoimmune, and cardiovascular diseases, including atherosclerosis, multiple sclerosis, and type 2 diabetes (MCC950 Sodium: Selective NLRP3 Inflammasome Inhibitor for...). Targeting the NLRP3 inflammasome allows dissection of disease mechanisms and the evaluation of anti-inflammatory interventions that are highly specific to this pathway. This article extends prior overviews by integrating recent endothelial cell pyroptosis data and defining MCC950 sodium’s translational positioning.

Mechanism of Action of MCC950 sodium

MCC950 sodium (also known as CRID3 sodium salt) selectively inhibits NLRP3 inflammasome assembly. It binds to the NACHT domain of NLRP3, preventing ATP hydrolysis and oligomerization required for inflammasome activation (Yuan et al. 2022). The compound exhibits an IC50 of 7.5 nM in murine bone marrow-derived macrophages (BMDMs) and similar potency in human monocyte-derived macrophages (HMDMs). MCC950 sodium blocks both canonical (e.g., LPS+ATP) and noncanonical (e.g., cytoplasmic LPS) NLRP3 activation, but does not inhibit AIM2, NLRC4, or NLRP1 inflammasomes. This specificity is confirmed by the selective inhibition of IL-1β secretion without affecting tumor necrosis factor-α (TNF-α) or inflammasome-independent cell death. The mechanism is independent of upstream priming signals and directly targets the NLRP3 activation step.

Evidence & Benchmarks

• MCC950 sodium (10 μM, 2 h) robustly suppresses IL-1β release in H2O2-induced pyroptosis models of human umbilical vein endothelial cells (HUVECs) (Yuan et al. 2022).
• In murine BMDMs, MCC950 sodium inhibits NLRP3 activation with an IC50 of 7.5 nM under LPS/ATP stimulation (APExBIO).
• Selective inhibition: MCC950 sodium does not affect IL-1β release from AIM2, NLRC4, or NLRP1 inflammasomes (see Table 2, Yuan et al. 2022).
• In animal models, MCC950 sodium administered intraperitoneally reduces serum IL-1β and IL-6 levels after LPS challenge and attenuates disease severity in experimental autoimmune encephalomyelitis, a model for multiple sclerosis (Yuan et al. 2022).
• High aqueous solubility (≥124 mg/mL) and stability at -20°C facilitate reproducible experimental workflows (APExBIO).

This article clarifies and updates prior data by integrating mechanistic and translational insights from recent endothelial cell research (Advancing Translational Research: Strategic and Mechanist...).

Applications, Limits & Misconceptions

MCC950 sodium is a benchmark tool for dissecting NLRP3-driven inflammatory mechanisms in macrophages, endothelial cells, and animal models. It is suitable for:

• Studying NLRP3 inflammasome activation and inhibition in primary and immortalized macrophages.
• Elucidation of NLRP3 involvement in autoimmune and cardiovascular disease models (e.g., experimental autoimmune encephalomyelitis, atherosclerosis).
• Screening for NLRP3-dependent cytokine release (IL-1β, IL-18) without interfering with TNF-α or other inflammasome pathways.
• Evaluating therapeutic interventions that specifically modulate NLRP3 signaling in translational research (MCC950 Sodium: Selective NLRP3 Inflammasome Inhibition in...).

Common Pitfalls or Misconceptions

• MCC950 sodium does NOT inhibit other inflammasomes (AIM2, NLRC4, NLRP1); its action is specific to NLRP3 (Yuan et al. 2022).
• It does NOT block upstream priming events such as NF-κB signaling or pro-IL-1β synthesis.
• Long-term storage of MCC950 sodium solutions (>1 week) at room temperature can lead to degradation; always store at -20°C for stability (APExBIO).
• MCC950 sodium is not an approved therapeutic and should be used for research use only (RUO).
• Overdosing or incorrect solvent use (e.g., highly acidic or basic solutions) can reduce compound efficacy or solubility.

Compared to previous overviews (Rewriting Inflammation: Strategic Insights for Translatio...), this article delineates boundaries of MCC950 sodium’s mechanistic selectivity in cellular and in vivo models.

Workflow Integration & Parameters

Preparation: Dissolve MCC950 sodium in water (≥124 mg/mL), DMSO (≥21.45 mg/mL), or ethanol (≥43 mg/mL). Filter sterilize if required. Store powder at -20°C; avoid repeated freeze-thaw cycles. Prepare fresh solutions before use for maximum stability (APExBIO).

In Vitro Use: Treat murine BMDMs or human HMDMs with MCC950 sodium at 1–10 μM for 1–2 hours prior to NLRP3 stimulation (e.g., LPS ± ATP). Assess IL-1β release by ELISA or immunoblot. Confirm selectivity by measuring TNF-α or using AIM2/NLRC4 agonists as controls.

In Vivo Use: For mouse models, intraperitoneal administration at validated doses (e.g., 10–20 mg/kg) within 1 hour of inflammatory challenge (e.g., LPS, EAE induction). Monitor serum cytokines and disease scores. Reference detailed protocols in recent translational studies (Engineering the Next Frontier in Translational Inflammato...).

This workflow guidance extends prior mechanistic reviews by specifying solvent compatibility, dosing windows, and QC parameters for high reproducibility.

Conclusion & Outlook

MCC950 sodium (B7946, APExBIO) is a cornerstone tool for NLRP3 inflammasome research, providing unmatched specificity, potency, and reproducibility. Its validated use in both in vitro and in vivo models enables detailed mechanistic dissection of NLRP3-associated inflammatory and autoimmune processes. Ongoing research will refine its translational applications and may inform future therapeutic development targeting the NLRP3 inflammasome.

For further details or to order, visit the MCC950 sodium product page.